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prevalence and penetrance of BRCA
mutations
Familial susceptibility to breast cancer accounts for 25% of all
breast cancer cases. In familial breast cancer, mutations in
BRCA1, BRCA2, CHEK2, TP53 and PTEN genes account
for 5%–10% of breast and ovarian cancer cases overall.
BRCA1 and BRCA2 are high-penetrance breast cancer
predisposition genes while mutations in CHEK2, ATM, BRIP1
and PALB2 are rare and confer an intermediate risk of breast
cancer. Association studies have further identified other
common variants associated with low-penetrance breast cancer
predisposition. Nevertheless, >70% of the genetic
predisposition to breast cancer remains unexplained.
The estimated population frequency of mutations in BRCA1/
2 genes is 1/800 to 1/1000 per gene. Overall this equates to
15%–20% of the excess familial risk of breast cancer. The
prevalence of BRCA1 or BRCA2 germline mutations varies
considerably among ethnic groups and geographical areas.
Population-specific mutations and recurrent mutations have
been described among Ashkenazi Jews, in Iceland, the
Netherlands, Sweden, Norway, Germany, France, Spain,
Canada, and countries of eastern and southern Europe.
BRCA1 and BRCA2 mutation frequencies in breast and
ovarian cancer patients unselected for family history or age at
onset are generally low (<1%–7% for BRCA1 and 1%–3% for
BRCA2). Higher prevalence is associated with a family history
of breast or ovarian cancer, young age at onset, male breast
cancer or multiple tumours (bilateral breast cancer or breast
and ovarian cancer in the same patient).
Based on pooled data from cases unselected for family
history it is estimated that average cumulative risks in BRCA1-
mutation carriers by age 70 years were 65% [confidence interval
(CI) 44%–78%] for breast cancer and 39% (18%–54%) for
ovarian cancer. The corresponding estimates for BRCA2 were
45% (31%–56%) and 11% (2.4%–19%). The relative risk of
male breast cancer is elevated for both genes, particularly
BRCA2 (6%). An elevated risk of prostate cancer has also been
shown in BRCA2 carriers, particularly in men aged <65 years.
Other cancers at increased risk are pancreatic (up to 2%),
stomach, and head and neck.
referral for BRCA testing
Genetic testing criteria may differ between countries based on
mutation prevalence. Widely accepted clinical criteria for
referral include: three or more breast and/or ovarian cancer
cases, at least one <50 years; two breast cancer cases <40 years;
male breast cancer and ovarian cancer or early onset female
breast cancer; Ashkenazi Jew with breast cancer of <60 years,
young onset bilateral breast cancer, and breast and ovarian
cancer in the same patient [IV, C]. In some countries, the
criterion for testing is based on an a priori 10%–20%
probability of finding a mutation based on predictive models
such as BRCAPRO, BOADICEA or Manchester Score, while
less specific criteria include a potential benefit in the medical or
surgical management of the individual or his/her relatives.
Pathological features of breast cancer such as medullary
carcinoma and triple negative phenotype (estrogen receptor,
progesterone receptor and no overexpression of HER2neu). In
all cases, genetic testing should be performed in adults,
usually >25 years old, after having received genetic counselling
and informed consent. Carriers should be encouraged to advise
close family members to obtain genetic counselling.
mutation detection
The majority of clinically significant deleterious mutations are
protein-truncating mutations and a small number are missense
mutations. Several mutation detection techniques are in use,
but direct DNA sequencing is the gold standard. Genomic
DNA, extracted from blood is used as a template and coding
exons with flanking intronic sequences are analysed. In
addition, since 2%–12% of high-risk families may harbour
a large genomic alteration, specific techniques to detect
duplications or deletions of one or more exons such as
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multiplex ligation-dependent probe amplification (MLPA) are
recommended [III, B].
risk reduction: non-surgical preventive
options
surveillance
Surveillance of breast cancer in BRCA carriers includes monthly
self-examinations, clinical breast examinations twice a year,
yearly mammograms and magnetic resonance imaging (MRI)
of breasts starting at age 25–30 [IIa, B]. There are yet no data
available to determine whether alternating mammogram and
MRI every 6 months or having both once yearly is more
effective at young ages, considering the high rate of interval
cancers.
chemoprevention
Adjuvant tamoxifen reduces the risk of contralateral breast
cancer in affected BRCA mutation carriers [III, B], while the
benefit of tamoxifen for primary prevention of breast cancer in
BRCA carriers has not been demonstrated [Ib, A].
risk reduction: prophylactic surgical
options
prophylactic bilateral mastectomy
It is the most effective strategy available for risk reduction of
breast cancer in mutation carriers [III, B], although no benefit
in survival has been demonstrated and many women do not
find this strategy acceptable for cosmetic reasons. Contralateral
prophylactic mastectomy is an option to consider in those
BRCA mutation carriers with early breast cancer undergoing
unilateral mastectomy [III, B].
Types of prophylactic mastectomy may range from total
mastectomy to skin-sparing mastectomy, and nipple-sparing
mastectomy. The different options should be discussed with the
patient and include the benefits and risks for each. A
concurrent discussion of the benefits and risks of immediate
breast reconstruction should be approached.
At this time, there is insufficient evidence to recommend
routine sentinel node biopsy for patients undergoing
prophylactic mastectomy.
prophylactic bilateral salpingo-oophorectomy
There is evidence that it is associated with a primary risk
reduction of breast cancer in premenopausal BRCA
mutation carriers (statistically significant for BRCA2), risk
reduction of ipsilateral breast cancer recurrence after
breast conserving surgery and radiotherapy, risk reduction of
ovarian and gynaecological cancer, and reduction in overall
mortality [III, B]. Bilateral salpingo-oophorectomy is
recommended after age 35 and when childbearing decisions are
complete [IV, C].
Short-term hormonal replacement therapy after
bilateral salpingo-oophorectomy seems not to decrease the
overall benefit of this strategy for breast cancer risk reduction
[III, B].
risk modifiers
BRCA-associated breast cancer risk can be modified by external
factors. Hormonal and reproductive factors such as pregnancy
(number and age at first pregnancy), history of breast feeding
and oral contraceptives have been associated with risk
modification in BRCA mutation carriers with contradictory
results. Parity seems to confer protection from breast cancer in
women with BRCA mutations as in the general population
[III, B].
breast cancer treatment
surgery
Breast conserving surgery and radiotherapy in BRCA mutation
carriers who undergo prophylactic oophorectomy have been
associated with a similar rate of ipsilateral breast recurrence
versus sporadic controls at 10 years. The risk of contralateral
breast cancer in BRCA carriers is higher versus sporadic
controls, regardless of hormonal intervention.
Decisions about the surgical treatment of breast cancer in
BRCA mutation carriers should be based on the same
parameters as sporadic cancer, while considering the overall
higher risk of contralateral breast cancer, and ipsilateral
recurrence if undergoing breast conserving surgery followed by
radiotherapy in those not performing oophorectomy [III, B].
systemic treatment
Current evidence suggests that overall prognosis of breast
cancer in BRCA carriers is similar to sporadic breast cancers
and BRCA1/2 deficiency seems to be predictive of
chemosensitivity [III, B].
An ongoing Phase II randomized clinical trial in the
metastatic setting is testing the sensitivity to platinum-based
chemotherapy of BRCA tumours versus taxane-based
treatment.
PARP inhibitors are being developed as single therapeutic
agents for BRCA breast and ovarian cancer patients. These
drugs inhibit a pathway of DNA single-strand break repair and
lead to apoptosis in BRCA-deficient cancer cells, which already
have a deficiency in homologous recombination repair. Several
Phase II trials are testing the specific DNA-repair deficiency of
BRCA-associated tumours with the use of PARP inhibitors in
the metastatic setting. Two Phase II trials with the oral PARP
inhibitor olaparib in advanced breast and ovarian cancer
patients with BRCA germline mutations have recently reported
an encouraging clinical efficacy at 400 mg bid continuously
(response rate: 41% and 33%, and progression-free survival: 5.7
and 5.8 months, respectively).
Up to now there is no definitive conclusion on the best
chemotherapy regimen for BRCA breast cancer patients [III, B].
Nowadays standard prognostic features should be used to
decide adjuvant treatment in BRCA mutation carriers with
breast cancer.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
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justified standard clinical practice by the experts and the ESMO
faculty.
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